| Literature DB >> 15374880 |
George Z Rassidakis1, Marianna Feretzaki, Coralyn Atwell, Ioannis Grammatikakis, Quan Lin, Raymond Lai, Francois-Xavier Claret, L Jeffrey Medeiros, Hesham M Amin.
Abstract
Anaplastic large cell lymphoma (ALCL) is a highly proliferative neoplasm that frequently carries the t(2;5)(p23;q35) and aberrantly expresses nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). Previously, NPM-ALK had been shown to activate the phosphatidylinositol 3 kinase (PI3K)/Akt pathway. As the cyclin-dependent kinase (CDK) inhibitor p27(Kip1) (p27) is usually not expressed in ALCL, we hypothesized that activated Akt (pAkt) phosphorylates p27 resulting in increased p27 proteolysis and cell cycle progression. Here we demonstrate that inhibition of pAkt activity in ALCL decreases p27 phosphorylation and degradation, resulting in increased p27 levels and cell cycle arrest. Using immunohistochemistry, pAkt was detected in 24 (57%) of 42 ALCL tumors, including 8 (44%) of 18 ALK-positive tumors and 16 (67%) of 24 ALK-negative tumors, and was inversely correlated with p27 levels. The mean percentage of p27-positive tumor cells was 5% in the pAkt-positive group compared with 26% in the pAkt-negative group (P = .0076). These findings implicate that Akt activation promotes cell cycle progression through inactivation of p27 in ALCL.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15374880 PMCID: PMC1382060 DOI: 10.1182/blood-2004-06-2125
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113